Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine

Table 4 Summary of current and lifetime diagnosis of comorbid diseases at baseline

Psychiatric diagnosis	EUR group	NE group	Total	p-value^a
	( N=1217)	( N=800)	( N=2017)
	n(%)	n(%)	n(%)
Alcohol Abuse
Current	2 (0.2)	0 (0.0)	2 (0.1)	.521
Lifetime	56 (4.6)	24 (3.0)	80 (4.0)	.080
Depressive Disorder, Not Otherwise Specified
Current	7 (0.6)	0 (0.0)	7 (0.3)	.047
Lifetime	110 (9.0)	37 (4.6)	147 (7.3)	<.001
Dysthymic Disorder^b
Current	21 (1.7)	0 (0.0)	21 (1.0)	<.001
Generalized Anxiety Disorder
Current	4 (0.3)	0 (0.0)	4 (0.2)	.157
Lifetime	22 (1.8)	5 (0.6)	27 (1.3)	.028
Obsessive-Compulsive Disorder
Current	2 (0.2)	0 (0.0)	2 (0.1)	.521
Lifetime	10 (0.8)	1 (0.1)	11 (0.5)	.059
Post-traumatic Stress Disorder
Current	4 (0.3)	0 (0.0)	4 (0.2)	.157
Lifetime	8 (0.7)	3 (0.4)	11 (0.5)	.542
Social Phobia
Current	7 (0.6)	0 (0.0)	7 (0.3)	.047
Lifetime	16 (1.3)	4 (0.5)	20 (1.0)	.105

Abbreviation: EUR = European; N = total number of patients; n = number of patients in the specified category; NE = non-European.
^ap-values are from Fisher's exact test.
^bLifetime Dysthymic Disorder diagnoses were not collected.

ISSN: 1753-2000